logo-loader
viewGenprex, Inc.

Genprex ramps up production of active agent for its lung cancer drug Oncoprex

The agreement with manufacturing partner Aldevron LLC provides for the production of Tumor Suppressor Candidate 2 plasmid DNA at full commercial scale

Genprex, Inc. - Genprex Inc ramping up production of the active agent for its lung cancer drug Oncoprex
A Phase I/II trial of Oncoprex combined with osimertinib for non-small cell lung cancer is planned for early 2021

Genprex Inc (NASDAQ:GNPX) is ramping up production of Tumor Suppressor Candidate 2 (TUSC2) plasmid DNA, which is the active agent for its lead lung cancer drug candidate Oncoprex.

A new agreement with manufacturing partner Aldevron LLC provides for the production of TUSC2 plasmid DNA at full commercial scale, Genprex said.

Genprex, based in Austin, Texas, said increasing manufacturing should also result in significantly lower costs per unit of product due to economies of scale.

READ: Genprex set to join elite group of companies on the Russell 3000 Index

Boosting production comes as Genprex plans for upcoming clinical trials that include a Phase I/II trial of Oncoprex combined with osimertinib -- marketed by AstraZeneca PLC (NYSE:AZN) as Tagrisso -- for non-small cell lung cancer (NSCLC).

The study received Fast Track Designation from the US Food and Drug Administration in January 2020 and is expected to be initiated in early 2021.

In addition, a clinical trial of Oncoprex in combination with pembrolizumab -- marketed by Merck & Co Inc (NYSE:MRK) as Keytruda -- in NSCLC is also planned.

“We are pleased with continued progress in the scale-up of our manufacturing processes,” Genprex CEO Rodney Varner said in a statement.

“This new agreement with Aldevron increases our manufacturing capabilities in support of our clinical trials utilizing Oncoprex immunogene therapy in combination with targeted therapies and immunotherapies against lung cancer,” he added. 

The company’s stock recently traded up 1% to $3.03 a share in New York. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Genprex, Inc.

Price: 3.59 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $139.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read